The ability to unfold a protein and return it to its original state could save money in everything from cancer research to food production.» Read More
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.
CNBC biotech and pharma reporter Meg Tirrell looks at what to expect from the biggest and most important health care conference of the year. The 33rd annual J.P. Morgan Health Care Conference starts Monday, with 450 companies presenting to almost 9,000 attendees.
Biotech investor Brad Loncar is on a mission to persuade every presenting company at an upcoming biotech conference to also webcast its breakout session.
Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.
A new family of powerful antibiotics may provide a weapon against the growing threat of drug-resistant superbugs. NBC News reports.
This year’s flu season is shaping up to be as bad as expected. That's good news for drug stores, but insurers and others could suffer.
Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic.
A new drug activates receptors in the intestine, tricking the body into thinking it has just eaten a meal.
Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.
Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.
Rather than pay so much out-of-pocket, many skip checkups and scrimp on care, USA Today reports.
Express Scripts says its largest plan will cover only AbbVie's hepatitis C regimen, excluding drugs from Gilead and J&J.
This flu season is ramping up earlier than last year's, NBC News reports.
Hallucinogenic mushrooms have been discovered on the grounds of Buckingham Palace in London, NBC News reports.
Infections resistant to medicine will kill more people per year than cancer, and cost the world $100 trillion annually by 2050, according to a report.
Philadelphia's transit agency has filed a lawsuit against Gilead Sciences challenging the "exorbitant pricing" of its hepatitis C drug Sovaldi.
Get the best of CNBC in your inbox